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Abstract
Objective: The platelet collagen receptor glycoprotein VI (GPVI) has an independent 
role as a receptor for fibrin produced via the coagulation cascade. However, various 
reports of GPVI binding to immobilized fibrin(ogen) are not consistent. As a collagen 
receptor, GPVI- dimer is the functional form, but whether GPVI dimers or monomers 
bind to fibrin remains controversial. To resolve this, we analyzed GPVI binding to nas-
cent fibrin clots, which more closely approximate physiological conditions.
Methods and results: ELISA using biotinyl- fibrinogen immobilized on streptavidin- 
coated wells indicated that GPVI dimers do not bind intact fibrinogen. Clots were 
formed by adding thrombin to a mixture of near- plasma level of fibrinogen and re-
combinant GPVI ectodomain: GPVI dimer (GPVI- Fc2 or Revacept) or monomer (GPVI- 
His: single chain of Revacept GPVI domain, with His tag). Clot- bound proteins were 
analyzed by SDS- PAGE/immunoblotting. GPVI- dimer bound to noncrosslinked fibrin 
clots with classical one- site binding kinetics, with µM- level KD, and to crosslinked 
clots with higher affinity. Anti- GPVI- dimer (mFab- F) inhibited the binding. However, 
GPVI- His binding to either type of clot was nonsaturable and nearly linear, indicating 
very low affinity or nonspecific binding. In clots formed in the presence of platelets, 
clot- bound platelet- derived proteins were integrin αIIbβ3, present at high levels, and 
GPVI.
Conclusions: We conclude that dimeric GPVI is the receptor for fibrin, exhibiting a 
similar KD to those obtained for its binding to fibrinogen D- fragment and D- dimer, 
suggesting that fibrin(ogen)'s GPVI- binding site becomes exposed after fibrin forma-
tion or cleavage to fragment D. Analysis of platelets bound to fibrin clots indicates 
that platelet GPVI binds to fibrin fibers comprising the clot.
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1  |  INTRODUC TION
To maintain hemostasis, thrombus formation is initiated when flowing 
blood contacts exposed subendothelial tissues of injured blood ves-
sels, activating two reaction pathways. One pathway involves bind-
ing of the platelet- specific collagen receptor glycoprotein VI (GPVI) to 
subendothelial collagen exposed in injured vessels, initiating a signal-
ing cascade leading to platelet activation, aggregation, and thrombus 
formation.1- 4 Constitutively present GPVI dimers comprise 29% of the 
total GPVI (monomers and dimers) in resting platelets. The dimers bind 
with high affinity to collagen fibers, but not soluble monomeric colla-
gen,2 and are the functional form of this receptor.5,6 Platelet activation 
increases the number and clustering of dimers, bringing signaling mol-
ecules into closer proximity to enhance platelet activation.7
The second pathway occurs simultaneously, driven by tissue factor 
release from damaged sub- endothelium that produces active thrombin 
through the coagulation cascade; thrombin converts fibrinogen in blood 
to fibrin monomers, which then polymerize to form a gel- like fibrin clot. 
Clots are stabilized by activated factor XIII, factor XIIIa, which catalyzes 
fibrin crosslinking. Thrombin also activates nearby platelets, leading to 
phosphatidylserine expression and formation of a prothrombinase com-
plex with coagulation factors V and VIII, enhancing thrombin formation, 
further driving fibrin formation and platelet activation. Many blood cells, 
including platelets are trapped within the fibrin clot and numerous fibri-
nolysis- and coagulation- related proteins are bound to the fibrin fibrils.8 
Many of these proteins, such as α2- plasmin inhibitor, plasminogen, von 
Willebrand factor (VWF), fibronectin, and albumin,9- 11 are covalently 
crosslinked to fibrin by factor XIII and affect fibrin clot stability. Intravital 
microscopy has detected fibrin fibers at the site of injury, and thrombi 
with tightly packed and activated platelet cores were formed in the in-
travascular space over the injured site.12,13 Loosely adherent platelets 
formed a shell- like layer outside the platelet core.12
Recently, GPVI was reported to bind both fibrin and fibrinogen, in-
dependent of its function as a collagen receptor, leading to platelet ac-
tivation.14,15 Thus, thrombus formation is a process combining platelet 
activation and blood coagulation, with GPVI involved in both systems. 
Details about this role of GPVI in coagulation, whether there is direct 
binding to both fibrin and fibrinogen, and whether GPVI- monomer 
or - dimer can serve as the receptor remain controversial. Watson's 
group reported that GPVI monomer binds to fibrin and fibrinogen, 
whereas the dimer does not, using assays with immobilized fibrin or 
fibrinogen.16,17 However, in our hands, these results could not be re-
produced by a similar ELISA method using a fully glycosylated dimeric 
recombinant Fc- fusion protein of the GPVI- extracellular domain 
(GPVI- Fc2) and indeed we found the opposite results. We found that 
GPVI- Fc2 scarcely bound to fibrin, and not to fibrinogen at all, but did 
bind to a part of the fibrinogen molecule, the D- fragment, and to the 
crosslinked fibrin degradation product D- dimer, both with one- site 
binding kinetics.18 We found that the corresponding GPVI- monomer 
did not bind well to any of these fibrinogen substrates in ELISA as-
says,18 which was later confirmed by Zhang et al.10 Using a different 
analysis system, Ebrahim et al19 reported that GPVI- dimer does not 
bind to fibrin under flow conditions.
In the present studies, we developed a method to quantitate the 
binding of GPVI- dimer and - monomer to fibrin clots formed from 
fibrinogen by thrombin in the presence of GPVI. Our system avoids 
the shortcomings of ELISA assays that rely on immobilization of a 
low concentration of soluble fibrin. Interaction of GPVI with such 
immobilized fibrin or fibrinogen would be very different from the 
interaction with fibrin clots formed with near- physiological con-
centrations of fibrinogen; such clots comprise larger fibrin fibers 
that have a characteristic three- dimensional structure and form a 
complex network. Whilst retaining the simplicity of a biochemically 
defined system, by studying the GPVI−fibrin interaction during clot 
formation, our assay method is closer to pathophysiology.
Fibrin protofibrils are formed by the polymerization of fibrin 
monomers, produced by thrombin cleavage of the fibrinopeptide 
A from the E- domain of fibrinogen. The fibrin E- domain can now 
interact with the D- domain of another fibrin(ogen) molecule, in-
ducing a conformational change and fibrin- specific structure in the 
D- domain, which is the binding site for plasminogen and tissue plas-
minogen activator.20,21 Fibrin- bound factor XIII is also activated by 
thrombin and catalyzes both fibrin−fibrin and also plasma protein−fi-
brin crosslinks. Fiber formation is a very complex process, making it 
imperative that we understand the basic interaction between fibrin 
and each specific ligand, in this case GPVI, in a defined system as the 
first step in the absence of other proteins.
Our results indicate that GPVI- dimer binds specifically to fibrin 
clots but GPVI- monomer binds either nonspecifically or with very 
low affinity to the fibrin clots. We also suggest that GPVI contrib-
utes significantly to the binding of resting platelets to fibrin. We 
demonstrate here that the collagen- binding GPVI- dimer is the form 
that also binds specifically to fibrin clots.
2  |  MATERIAL S AND METHODS
2.1  |  Materials
We used a fibrinogen that is a plasminogen- , VWF- , and fibronectin- 
depleted human fibrinogen preparation (fibrinogen- 3; Enzyme 
Research Laboratories). The fibrinogen was biotinylated using 
sulfosuccinimidyl- 2- [biotinamido] ethyl- 1,3- dithiopropionate (EZ- Link 
Essentials
• Glycoprotein VI (GPVI) was reported to bind to fibrin 
(ogen) but its mechanism is controversial.
• Fibrin clots formed with GPVI, fibrinogen, and thrombin 
were used to quantitate GPVI- binding.
• Only GPVI- dimer binds to the clots like a classical recep-
tor; the monomer does not.
• Platelet surface GPVI also binds to the clots, but integrin 
αIIbβ3 is the major fibrin receptor.
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sulfo- NHS- SS- biotin; Thermo Scientific) according to the manufac-
turer's instructions. Biotin incorporation was 0.712 mol biotin per 
mol fibrinogen, and the derivative's clotability was the same as the 
unlabeled fibrinogen. Fibrinogen was also labeled with AlexaFluor- 555 
using a labeling kit (Invitrogen); 0.65 mol AlexaFluor- 555 was incor-
porated per mol fibrinogen. Dimeric forms of GPVI, GPVI- Fc2 and 
Revacept, were previously reported. GPVI- Fc2 contains the extracel-
lular domain of GPVI (amino acids 21- 234) fused with human IgG Fc, 
with C- terminal Myc and His tags.1 Revacept comprises amino acids 
21- 269 fused with IgG Fc with a C- terminal His tag.22 Both are fully 
glycosylated. Single- chain GPVI- His consists of amino acids 21- 269 of 
GPVI, with a C- terminal His- tag. Revacept and GPVI- His were kindly 
supplied by AdvanceCore (Martinsried).
The following antibodies were used in western blotting: anti- 
GPVI (1G5; binds to monomeric and dimeric GPVI; Biocytex), anti- 
GPIb (clone 486805; R&D Systems), anti- CD61 (clone VIPL2; Novus 
Biologicals), anti- human albumin (15C7; Abcam), and rabbit anti- 
tubulin (EPR16774, Abcam). Anti- integrin αIIbβ3 antibody M148 
(Abcam) was labeled with an AlexaFluor- 488 labeling kit (Invitrogen). 
Fluorescently labeled secondary antibodies were from Li- Cor 
Biosciences. The inhibitory GPVI dimer−specific antibody mFab- F 
has been reported previously.3
2.2  |  ELISA analysis of GPVI binding to 
biotinylated fibrinogen
ELISA- plate (Nunc MaxiSorp flat- bottomed; Thermo Fisher 
Scientific) wells were coated with streptavidin (10 μg/ml; Sigma); 
blocked with 0.5% bovine serum albumin (BSA); reacted with biotin- 
fibrinogen (10 μg/ml); and blocked with 10 μM biotin. After the final 
wash, wells were incubated with GPVI- Fc2 followed by 1G5/IR Dye 
800CW anti- mouse antibody, and binding was quantitated by the Li- 
Cor Odyssey CLx Imaging System. Fibrinogen preparations were also 
directly immobilized and GPVI- Fc2 binding was similarly measured.
2.3  |  Washed platelet preparation
Citrate- anticoagulated blood from healthy volunteers was obtained 
with informed consent in accordance with the Treaty of Helsinki. 
Washed platelets were prepared as described previously23 and re-
suspended in modified HEPES- Tyrode's buffer (HT: 134 mM NaCl, 
0.34 mM Na2HPO4, 2.9 mM KCl, 12 mM NaHCO3, 10 mM N- 
2- hydroxyethylpiperazine- N'- 2- ethanesulfonic acid, 5.5 mm glucose, 
pH 7.3).
2.4  |  Quantitative analyses of GPVI binding to 
fibrin clots
The reaction mixture consisted of fibrinogen (1 mg/ml, final con-
centration) and equal concentrations of GPVI- Fc2 and albumin 
(control protein). Thrombin (1 U/ml) was added, and the mixture 
was then incubated for 30 min at 37°C. Formed clots were pelleted 
by centrifugation at 14 000 rpm for 15 min in a microcentrifuge. 
The clots were washed twice with 0.5 ml of phosphate- buffered 
saline and dissolved in 0.1 ml of 1% SDS/8M urea solution. Each 
sample was mixed with 1/3 volume of SDS- sample buffer and 10 μl 
of each subjected to nonreduced SDS- PAGE and immunoblotting. 
The blots were stained with a mixture of 1G5 (mouse anti- pan 
GPVI) and anti- mouse albumin as primary antibodies and IRDye 
800CW anti- mouse antibody (LI- COR) as secondary antibody; 
GPVI- Fc2 and albumin bands were quantitated by the Odyssey 
image analyzer. Because GPVI- Fc2 and the control protein were 
stained using different primary antibodies, we normalized the 
GPVI and control protein bands to a normalization standard (ap-
plied to the same gel), which was a sample containing 25 μg/ml 
each of GPVI- Fc2 and control protein, as well as fibrinogen, with 
no added thrombin, which was then subjected to nonreduced SDS- 
PAGE/Western blotting along with the clot samples. The amounts 
of GPVI- Fc2 or control protein in the fibrin clots were calculated 
as a percent of the respective bands in the normalization stand-
ard, and the specific binding is deduced from the difference in the 
percent of the GPVI- Fc2 band and that of the control band at each 
GPVI- Fc2 concentration.
To quantitate GPVI- Fc2 binding to crosslinked fibrin clots, the 
reaction mixture contained fibrinogen (1 mg/ml final concentra-
tion), equal concentrations of GPVI- Fc2 and human Fc (control pro-
tein), Ca2+ (2 mM) and FXIII (2 μg/ml). Clot formation was induced by 
adding thrombin as described previously. The obtained crosslinked 
clots were each washed as described above and then dissolved 
with SDS/urea containing 2% 2- mercaptoethanol and subjected to 
reduced SDS- PAGE/western blotting. The blots were stained with 
IRDye 800CW anti- human antibody (LI- COR). GPVI- Fc and human 
Fc were quantitated as described previously and expressed as a 
percent of the normalization standard (25 μg/ml each of GPVI- Fc2 
and human Fc).
For quantitation of GPVI- His in either noncrosslinked or cross-
linked clots, the western blots were stained with mouse anti- His an-
tibody (Abcam, primary antibody) and IRDye 800 CW anti- mouse 
antibody (secondary antibody).
2.5  |  Effects of inhibitors on GPVI- Fc2 binding to 
fibrin clot
We determined how other GPVI- binding proteins: fibrinogen 
D- fragment, D- dimer, CRP- XL (crosslinked collagen- related 
peptide, a GPVI- specific agonist; synthesized by the Farndale 
lab), and mFab (anti- GPVI dimer) affected GPVI- Fc2 binding to 
the clots. Each mixture of GPVI- Fc2, fibrinogen, and test pro-
teins was preincubated for 10 min and then clotting initiated by 
adding thrombin. The clots were then processed as described 
above and analyzed for fibrin- bound GPVI- Fc2 by SDS- PAGE/
immunoblotting.
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2.6  |  Analysis of platelet receptor binding to 
fibrin clots
Washed platelets (5 × 108/ml in HT) were mixed with fibrinogen 
(1 mg/ml) in the absence or presence of human IgG Fab fragment 
(200 μg/ml; Jackson ImmunoResearch Laboratories), mFab- F 2,3 
(200 μg/ml), or Integrilin (10 μM, Sigma); clots were formed by add-
ing thrombin (1 U/ml), as described previously. To reduce extensive 
fibrin crosslinking, all the reactions contained 20 μM ZED1301 (FXIII 
inhibitor; Zedira). Each clot was mixed with an equal volume of lysis 
buffer (2% NP- 40, 150 mM NaCl, 50 mM Tris, pH 7.4, containing 
1/100 volume of protease inhibitors cocktail and phosphatase inhib-
itors cocktail [Merck]) and incubated for 30 min on ice. Lysates were 
slowly rotated overnight at 4°C. The fibrin clots were pelleted by 
centrifugation, washed twice with 1% NP- 40 lysis buffer, dissolved 
in SDS/urea solution, and analyzed by SDS- PAGE/immunoblotting. 
We also determined if other major platelet surface receptors (GPIb, 
integrin β3) and tubulin were associated with the clots. Because 
some proteins are precipitated in the cytoskeletal fraction under 
similar conditions, platelets in the absence of fibrinogen were also 
treated with lysis buffer at a 2- min incubation time, and the rela-
tive amount of the platelet proteins were calculated. The original 
sample containing platelets and fibrinogen is dissolved directly with 
SDS sample buffer and used as control for calculating the relative 
amounts of protein in each condition. The amount of clot- bound pro-
tein is expressed as relative amount to the corresponding band in the 
control sample.
2.7  |  Confocal imaging of platelet binding to 
fibrin clots
Each clotting mixture contained 80% unlabeled fibrinogen and 20% 
Alexa Fluor 555- labeled fibrinogen (total fibrinogen concentration 
of 1 mg/ml). After adding thrombin (0.2 U/ml) to the mixture, it was 
immediately pipetted into a well of an 8- chamber Nunc Lab- Tek II 
Chamber slide (Thermo Scientific). The formed clots on the slides 
were stored at 4°C overnight and then treated with a 1/100 dilution 
of Protease Inhibitor Cocktail, washed twice with PBS, and blocked 
with 1% BSA/PBS for 1 h before use.
Washed platelets in HT buffer (100 μl of 3- 5 × 107 platelets/
ml), added with hFab (human Fab, 100 μg/ml), mFab- F (100 μg/
ml), or Dasatinib (50 nM), were aliquoted over the clot on the 
slide. After 30 min at 37°C, the unadhered platelets were dis-
carded; clots washed four times with PBS; 200 μl of formalin 
was added and incubated for 10 min to fix the samples, followed 
by thorough washing with PBS. Samples were stained with 
AlexaFluor- 488- labeled M148 (anti- αIIbβ3, 4 μg/ml in 0.5% BSA/
PBS). Vectashield (nonhardening formula; Vector Laboratories) 
was dropped over the sample and a coverslip placed over it. The 
samples (coverslip- side down) were imaged with an FV300 IX81 
laser- scanning confocal microscope, with a ×60 oil immersion ob-
jective (Olympus UK).
2.8  |  Statistical analyses
The paired t- test was applied to compare the data using Prism ver-
sion 8 software (GraphPad).
3  |  RESULTS
3.1  |  GPVI- Fc2 does not bind to fibrinogen
We previously reported,18 assessed by ELISA, that GPVI- Fc2 bound 
strongly to fibrinogen D- fragment, but only very weakly to fibrino-
gen. Because others17 reported that GPVI monomers bound to fi-
brinogen, we verified that the lack of binding to fibrinogen was not 
due to steric hinderance, conformational change, or limited expo-
sure of its binding site because of directly immobilizing it on poly-
styrene wells or other surface.24 We examined GPVI- Fc2 binding to 
fibrinogen by using biotinylated fibrinogen indirectly immobilized to 
streptavidin- coated wells; less than one biotin molecule was incor-
porated per fibrinogen molecule, so most of the fibrinogen would be 
immobilized by a single biotin- streptavidin bond. GPVI- Fc2 bound 
to neither indirectly immobilized nor directly immobilized fibrino-
gen, but showed strong, saturable binding to fibrinogen fragment D 
(Figure 1), verifying that it does not bind to intact fibrinogen.
3.2  |  GPVI- Fc2 binding to fibrin clots
We developed an assay to measure GPVI- Fc2 binding to fibrin clots. 
In this assay, the bound proteins on fibrin clots are separated from 
the unbound form in solution by centrifugation to form pellets and 
by thoroughly washing the pellets with buffer. The fibrin pellets are 
then dissolved in SDS/urea solution and the amounts of GPVI- Fc2 
are analyzed by immunoblotting.
The validity of our assay was shown by the following results: 
(1) very little albumin or human Fc, used to determine nonspecific 
binding, was bound to the clots, so the procedures were sufficient 
to remove the unbound proteins trapped in the gel. (2) In our analy-
ses, the normalization control sample containing 25 μg/ml GPVI- Fc2, 
and 187.5 ng of protein is applied to SDS- PAGE after mixing with 
sample buffer. Figures 2 and 3 show that most of the GPVI bands 
are less than 80% of the control band, which corresponds to 150 ng 
at most. There is an almost linear correlation between the amount 
of GPVI- Fc2 applied to SDS- PAGE and protein band strength up 
to about 150 ng (Figure 4), validating our method for quantitative 
measurement.
GPVI- Fc2 bound specifically to the noncrosslinked fibrin clots 
with typical saturation kinetics, consistent with a classical one- site 
receptor; KD values ranged from 111.4 (Figure 2B graph) to 248.4 μg/
ml (mean ± SD = 1.19 ± 0.26 μM, n = 4).
GPVI- Fc2 binding to crosslinked clots was examined by in-
cluding Ca2+ (2 mM) and FXIII (2 μg/ml) in the clotting mixtures; 
these more- resistant clots were dissolved in 1% SDS/8M urea/2% 
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mercaptoethanol and detected as GPVI- Fc (single chain) by anti- 
human IgG antibody because 1G5 does not react with reduced 
GPVI. GPVI- Fc2 also binds specifically to the crosslinked clots, but 
its affinity was increased by about 2.4- fold; KD = 81.66 μg/ml for the 
Figure 3 curve (0.496 ± 0.166 μM, n = 4).
3.3  |  Analysis of GPVI monomer binding to 
fibrin clot
We compared the binding of dimeric and monomeric GPVI to fibrin 
clots by using fully glycosylated proteins having the same amino acid 
sequence with respect to the GPVI portion: Revacept (GPVI- dimer), 
a recombinant dimeric protein comprising two chains of the extra-
cellular domain of GPVI, and GPVI- His, which contains a single chain 
of the same GPVI extracellular domain, and hence serves as GPVI 
monomer in these experiments. Binding curves for Revacept were 
similar to those obtained for GPVI- Fc2 binding to noncrosslinked 
and crosslinked clots, with KD values of 1.18 ± 1.32 μM (n = 2) and 
0.62 ± 0.17 μM (n = 2), respectively (Figure 5B). These are similar to 
the corresponding values determined for GPVI- Fc2, and crosslinking 
increases Revacept affinity by about twofold, as it did for GPVI- Fc2.
In marked contrast, binding curves of GPVI- His are almost linear 
and nonsaturating (Figure 5A), suggesting that the binding of GPVI 
monomer to the fibrin clots is nonspecific or of very low affinity. 
Crosslinking fibrin did not affect GPVI- His binding.
3.4  |  The effects of inhibitors on GPVI- Fc2 binding 
to fibrin clots
We examined how proteins that interfere with the interaction be-
tween GPVI- Fc2 and fibrinogen fragment- D or D- dimer affect dimer 
binding to the clot (Figure 6). The inhibitory GPVI- dimer- specific 
antibody mFab- F partially but significantly inhibited the GPVI- Fc2 
binding to the clot (100 μg/ml, p = .070; 150 μg/ml, p = .0014; 
200 μg/ml, p = .0019 n = 6), indicating a GPVI- dimer- specific inter-
action. Fragment- D and D- dimer weakly inhibited (p = .0129 and 
p = .0235, respectively), supporting the conclusion that GPVI- Fc2 
binds to these fragments.18 Although the GPVI- specific agonist 
F I G U R E  1  ELISA analysis of GPVI- Fc2 binding to immobilized 
fibrinogens. Biotinylated fibrinogen was immobilized to 
streptavidin- coated wells and fibrinogen, biotin- fibrinogen, and 
fibrinogen D fragment were directedly immobilized on the wells 
of the ELISA plate. After washing, fibrinogen- coated wells were 
reacted with different concentrations of GPVI- Fc2 for 1 h and the 
bound GPVI- Fc2 was detected by 1G5 (anti- GPVI primary antibody, 
5 μg/ml)/IR 800CW anti- mouse IgG (secondary antibody). ○, biotin- 
fibrinogen immobilized on streptavidin- coated surface; ▲, biotin- 
fibrinogen directly immobilized on surface; ▲, nontreated fibrinogen 
directly immobilized; ●, fibrinogen fragment D directly immobilized. 
GPVI- Fc2 bound to fibrinogen fragment D in a dose- dependent and 
saturable manner. However, GPVI- Fc2 did not bind to any of the 
immobilized intact fibrinogens, regardless of if they were directly or 
indirectly immobilized on the surface. GPVI, glycoprotein VI; GPVI- 
Fc2, GPVI- extracellular domain; IgG, immunoglobulin G
F I G U R E  2  GPVI- Fc2 binding to noncrosslinked fibrin clot. Details of the preparation of the fibrin clot and quantitation of the fibrin- 
bound GPVI are described in the Methods. (A) A typical gel pattern for analyzing fibrin- bound GPVI- Fc2 by our method. (B) The quantitative 
relationship between the amount of GPVI- Fc2 and band strength; total clot- bound GPVI- Fc2 and albumin (nonspecific binding) are expressed 
as a percent of the normalization standard (clotting mixture containing 25 μg/ml each of GPVI- Fc2 and albumin, but no added thrombin). 
Specific binding of GPVI- Fc2 (%, red circles) is calculated by subtracting nonspecific binding (albumin, %, black squares) from the total 
binding of GPVI- Fc2 (%, black circles) and fit to a one- site binding model (red curve). The GPVI- Fc2 binding to the clot is dose- dependent 
and saturable, exhibiting classical receptor binding kinetics. GPVI, glycoprotein VI; GPVI- Fc2, GPVI- extracellular domain
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CRP- XL strongly inhibited GPVI- Fc2 binding to fragment- D and D- 
dimer,18 it did not affect GPVI- Fc2 binding to fibrin clots.
3.5  |  Analysis of platelet receptor binding to 
fibrin clot
These data indicate that purified GPVI- Fc2 binds to fibrin clots, so 
we formed clots from a mixture of platelets and fibrinogen to ex-
amine how the platelet- surface receptors, GPVI, GPIb, and CD61 
(integrin β3 subunit), contribute to the interaction between platelets 
and fibrin in the clot.
Figure 7 shows representative gel patterns for the clot- bound 
(n = 13) and cytoskeleton- associated (n = 6) platelet- derived pro-
teins. GPIb is associated with both the fibrin clot and cytoskeleton, 
with similar strong staining observed in both. GPVI and CD61 were 
only in the clot. CD61 staining is significantly inhibited by the αIIbβ3 
inhibitor Integrilin (p < .0001, n = 13) and enhanced by mFab- F 
(p = .0034, n = 13). Clot- bound GPVI is increased in the presence of 
Integrilin (p = .0415, n = 13). However, we could not detect any ef-
fect of mFab- F on GPVI binding. The low intensity of the GPVI band 
combined with the weak inhibitory effect of mFab- F would account 
for lack of observed significant effect. Only a small amount of tubu-
lin is bound to fibrin and not affected by any of the inhibitors.
3.6  |  Confocal imaging of platelets bound to 
crosslinked and noncrosslinked clots
Fluorescently labelled fibrin clots were formed with or without 
crosslinking, and then washed platelets allowed to adhere to the 
clots, followed by staining for αIIbβ3. In the noncrosslinked clots, 
almost all the control platelets were round in shape with no pro-
trusions, suggesting that they are not activated, with only a few 
well- spread platelets observed. Particularly evident was the “halo” 
of fibrin, colocalizing with integrin αIIbβ3 on the platelet periphery. 
Dasatinib (tyrosine kinase inhibitor, which inhibits Src kinases) pre-
vented all spreading and decreased association with fibrin, but the 
platelets still adhered. mFab- F did not affect the platelet binding in 
four of six preparations, but there is apparently less fibrin bound 
around the platelet perimeter.
F I G U R E  3  GPVI- Fc2 binding to crosslinked fibrin clot. GPVI- Fc2 binding to crosslinked fibrin clot (formed in the presence of Ca
2+ and 
factor XIII) was analyzed as described in Figure 2 and the Methods. (A) Typical gel pattern for analyzing the GPVI- Fc2 binding to crosslinked 
fibrin clot. (B) Quantitative results. GPVI- Fc2 was reduced, and thus detected as GPVI- Fc with anti- human IgG antibody that detected the Fc 
portion of GPVI- Fc and the control protein was human Fc. After normalization with the standard, total binding of GPVI- Fc2 (black circles, %) 
was subtracted by the value for human Fc (black squares, %) to obtain specific binding of GPVI- Fc2 (%, red circles); specific binding was fitted 
to a one- site model. GPVI- Fc2 binding to the crosslinked clot is dose- dependent and saturable, but had higher affinity than its binding to the 
noncrosslinked clots. GPVI, glycoprotein VI; GPVI- Fc2, GPVI- extracellular domain
F I G U R E  4  Relationship between band strength and applied 
amount of GPVI- Fc2. Amount of GPVI- Fc2 as detected by our SDS- 
PAGE/Western blotting system nearly linearly increases with the 
amount of GPVI- Fc2 applied to SDS- PAGE. This validates that our 
system for analyzing GPVI- Fc2 binding to clots is quantitative in 
the concentration of GPVI- Fc2 that we used. GPVI, glycoprotein VI; 
GPVI- Fc2, GPVI- extracellular domain
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Platelets adhered to crosslinked clots had notably different mor-
phology. The control platelets were well- spread on crosslinked fi-
brin, and mFab- F did not affect this. Dasatinib appeared to decrease 
the number of well- spread platelets and the platelets had a spikey 
appearance. No sample had evident fibrin colocalized on the plate-
let periphery. These results suggest that resting platelets would be 
slightly activated on the fibrin fibers and the crosslinked fibrin would 
more strongly activate them, resulting in spreading.
4  |  DISCUSSION
Thrombus formation is a process combining platelet activation and 
blood coagulation, with platelet GPVI involved in both systems by 
functioning independently as a collagen receptor and fibrin recep-
tor, respectively. The collagen- binding functional form of GPVI has 
been established to be a dimer composed of two GPVI molecules, 
but there are ongoing controversies about which form of GPVI, the 
monomer or dimer, is the functional fibrin receptor and about the 
GPVI binding to fibrinogen or fibrin. Our present study aimed to re-
solve these issues.
The discrepant observations by different laboratories may 
arise from using ELISA assays with immobilized fibrinogen or fi-
brin, a system far from the physiological environment of this in-
teraction. ELISA cannot address the GPVI- fibrin- fiber interactions 
under physiological conditions, where platelets would interact 
with clots formed from a three- dimensional network of fibrin fi-
bers that have been crosslinked via the transglutaminase activity 
of FXIIIa. Physiologically, fibrin forms a gel- like clot at higher fi-
brinogen concentrations by thrombin. Fibrin has specific affinity 
for numerous plasma proteins, including plasminogen, factor XIII, 
fibronectin, VWF, and prothrombin25; and plasminogen binding to 
fibrin depends on fibrin structure.21 Thus, the artificially formed 
and immobilized fibrin used in ELISA assays, typically formed with 
fibrinogen concentrations <100 μg/ml, is in the soluble form (mo-
nomeric or partially polymerized fibrin) and as such has properties 
F I G U R E  5  Analysis of Revacept and GPVI- His binding to fibrin clots. Revacept, which contains 2 chains of the extracellular domain of 
GPVI, was used as GPVI- dimer and GPVI- His, comprised of one chain of the same GPVI- extracellular domain as Revacept, was used as 
GPVI- monomer. Binding was measured by the same methods as described in Figures 2 and 3. Revacept and GPVI- His were detected by 
1G5 or anti- human IgG and anti- His antibodies, respectively. (A) Typical curves for the binding of GPVI- His to noncrosslinked (left) and 
crosslinked fibrin (right) clots. The binding in the concentration range of 50 to 200 μg/ml is nearly linear, consistent with it being of very 
low affinity or nonspecific. Crosslinking the clots had no effect on GPVI- His binding. (B) Typical curves for the binding of Revacept to 
noncrosslinked fibrin (left) and to crosslinked fibrin (right). Revacept binding is dose- dependent and saturable and Revacept has a higher 
affinity for the crosslinked fibrin clot than the noncrosslinked one. □, total binding of Revacept or GPVI- His; ●, specific binding; ◊, binding of 
control proteins
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not fully reflecting those of fibrin fibers in physiological clots. The 
inhibition of GPVI- dependent platelet activation by GPRP, an in-
hibitor of fibrin clot formation,15- 17 supports our hypothesis that 
GPVI binds only to fibrin fibers. Here we developed a system to 
quantitatively determine GPVI dimer and monomer binding to fi-
brin fibers in clots to reconcile the different findings. We deter-
mined GPVI binding to fibrin clots formed from thrombin cleavage 
of near- serum concentrations of fibrinogen, which mimics the 
clots formed from a three- dimensional network of fibrin fibers as 
seen in vivo. Furthermore, we have used fully glycosylated recom-
binant proteins of the GPVI extracellular domain (GPVI- Fc2 and 
Revacept and GPVI- His, the one- chain form containing the same 
GPVI- domain as Revacept along with a His tag) to assess this in-
teraction, also removing further uncertainty caused by using trun-
cated or incompletely glycosylated recombinant proteins of the 
GPVI extracellular domain.
We verified that neither directly immobilized fibrinogen nor 
indirectly immobilized biotin- fibrinogen bound to GPVI- Fc2, but 
observed binding of fibrinogen D- fragment that was concentration- 
dependent and saturable (Figure 1), as reported previously. This sug-
gests that the GPVI- dimer binding site in the D- domain of fibrinogen 
is not exposed to the surface in an intact fibrinogen molecule and its 
processing by the coagulation cascade to fibrin is required to make 
these sites available.
In our clot assay, GPVI- Fc2 shows a typical one- site binding 
curve with a KD of 1.19 ± 0.26 μM for noncrosslinked fibrin and 
0.50 ± 0.17 μM for crosslinked fibrin, but this was not a significant 
difference (p = .065). These KD values are similar to the KD (0.3- 
0.4 μM) that we reported for GPVI- Fc2 binding to immobilized D 
fragment or D- dimer18 by ELISA and similar to its KD (0.576 μM) for 
collagen as measured by surface plasmon resonance.1 GPVI dimer, 
and not GPVI monomer, was indicated to bind to collagen fibers 
that are prepared from collagen gel but GPVI dimer does not bind to 
soluble (mostly monomeric) collagen.23 The GPVI- dimer binding to 
fibrin clots is inhibited by the GPVI- dimer- specific antibody mFab- F 
(Figure 6), and this is weakly inhibited by fragment D and D- dimer, a 
consistent set of observations. The modest effect of fragment D or 
D- dimer is reasonable because each is competing with a high con-
centration of fibrin. CRP- XL, however, was not inhibitory, although 
it strongly inhibited GPVI- Fc2 binding to fragment- D or D- dimer,
18 
suggesting that
GPVI- Fc2 binding sites for fibrin and fragment D would be slightly 
different and CRP- XL would bind closely to the latter site. The bind-
ing site of fibrinogen for GPVI dimer would be exposed after fibrin 
clot formation or proteolytic degradation by plasmin to fragment D. 
The reported conformational change in fibrinogen upon its conver-
sion to fibrin20,21 may enable GPVI dimer to access its binding site in 
the D- domain.
Revacept, whose structure is similar to GPVI- Fc2, specifically 
bound to noncrosslinked (KD = 1.18 ± 1.32 μM) and crosslinked fi-
brin clots (KD = 0.617 ± 0.172 μM; Figure 5B). In marked contrast, 
monomeric GPVI- His exhibited nonsaturating binding to either type 
of clot, consistent with either very low affinity or nonspecific bind-
ing to the clots (Figure 5A). The low affinity of GPVI- His could be 
deduced from its monovalency compared with bivalent Revacept. 
Onselaer et al16 and Mangin et al17 reported that GPVI- monomer 
bound to both fibrin and fibrinogen, with a KD of about 0.3 μM, 
but detected no GPVI- dimer binding. GPVI- His binding to fibrin in 
our experiments is nonsaturable, and we cannot explain why this 
nonsaturable binding is so high because the nonspecific bindings of 
the control proteins (albumin and IgG Fc protein) are much lower. 
GPVI- His might have a weak affinity for the fibrin clot and our assay 
method, which is more complex because the clot is a gel, may en-
hance the overall binding of GPVI- His. Previous papers16,17 did not 
F I G U R E  6  Effects of inhibitors on 
GPVI- Fc2 binding to fibrin clots. The 
effects of the anti- GPVI dimer- specific 
antibody mFab- F; collagen mimetic CRP- 
XL; fibrinogen fragment D, and D- dimer 
on GPVI- Fc2 binding to noncrosslinked 
fibrin were analyzed. The concentrations 
of each antagonist in μg/ml are given in 
parentheses. mFab- F significantly inhibits 
the binding at concentrations greater than 
100 μg/ml and fragment D and D- dimer 
weakly inhibited the binding at the highest 
concentration of 100 μg/ml. CRP- XL had 
no effect. *p < .05, **p < .01, compared 
with control (no added inhibitor). GPVI, 
glycoprotein VI; GPVI- Fc2, GPVI- 
extracellular domain
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report the concentration dependence of GPVI monomer binding to 
fibrin but nonetheless concluded that it binds to fibrin, despite satu-
rability of binding being ignored.
Interaction between fibrin and platelet- surface receptors αIIbβ3, 
GPVI, and GPIb were examined by our clot system. Fibrin clots were 
formed in the presence of platelets, the platelets were dissolved 
with platelet lysis buffer, and then proteins bound to fibrin were an-
alyzed by immunoblotting. The very low amount of β- tubulin (used 
as the negative control) detected in fibrin (Figure 7) indicated that 
our lysis condition successfully dissolves platelets and there is no 
retention of nonspecifically bound proteins in the fibrin fraction. 
Some platelet proteins other than GPVI and integrin β3 may also 
precipitate with the cytoskeleton under our lysis conditions, partic-
ularly GPIb.26,27 To exclude this possibility, we analyzed the proteins 
precipitated in the absence of fibrinogen. Similar amounts of GPIb 
were found in the cytoskeletal precipitate and in the fibrin clot, so 
F I G U R E  7  Analysis of the contribution of GPVI on platelet binding to fibrin clot. Fibrin clots were formed in the presence of platelets 
and the following clot- bound proteins originating from platelets were analyzed: GPIb/Gc (glycocalicin), CD61 (integrin β3), GPVI, and tubulin 
were measured. The platelet cytoskeleton of thrombin- activated platelets was also precipitated in separate experiments to compare the 
difference in associated proteins. We determined the effect of inhibitors on the amount of these associated proteins. (A) An example of the 
gel pattern used to analyze the clot and cytoskeleton- associated proteins from platelets. The immunoblots were stained with appropriate 
primary antibodies followed by fluorescently labeled secondary (see Methods) and quantitated by a Licor Odyssey scanner. R (negative 
control; no thrombin treatment), C (control, no added inhibitor), hFab (human Fab only control), mFab (mFab- F, anti- GPVI- dimer), Int 
(Integrilin, antagonist of integrin αIIbβ3), Plts (platelets; original sample, no treatment). (B) Summary of the quantitation of platelet proteins 
associated with the clot and platelet cytoskeleton. The amounts of protein bands were calculated as percent of the original number of 
corresponding bands in platelets shown in plts in the figure. GPIb/Gc is found in both the cytoskeleton and clot fractions. CD61 is only 
associated with the clot and is significantly inhibited by integrilin (****p < .0001, compared with the control) and increased by mFab- F 
(**p ≤ .005, compared to the control Fab [hFab]). GPVI is only associated with the clot fraction and integrilin that inhibits αIIbβ3 increases 
the amount of clot- associated GPVI (*p ≤ .05). GPVI, glycoprotein VI; GPVI- Fc2, GPVI- extracellular domain
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the GPIb associated with the fibrin clot can mainly be ascribed to 
its association with the cytoskeleton. GPIb was reported to bind 
to VWF in platelet adhesion to fibrin under flow conditions,28 but 
because our fibrinogen preparation is VWF- free, this interaction is 
not relevant to our assay. Both platelet- derived GPVI and integrin β3 
were detected significantly in the clots, indicating that the fibrin clot 
contains the platelet proteins specifically binding to fibrin. Integrilin 
markedly decreased clot- bound β3, indicating that active αIIbβ3 con-
tributes to platelet binding to fibrin. However, Integrilin increased 
the amount of clot- bound GPVI, suggesting that GPVI in platelets 
can bind to fibrin, in lieu of active αIIbβ3. This is consistent with 
our observation that αIIbβ3- deficient platelets from a Glanzmann's 
thrombasthenia patient retained low- level but significant binding to 
fibrin and fragment- D as assessed by both static and flow adhesion 
methods.18 Zhang et al10 analyzed the effect under flow conditions 
of an anti- GPVI antibody on platelet adhesion to fibrin made from 
purified fibrinogen and showed it to be inhibited by the antibody, 
supporting our results. However, the antibody did not inhibit platelet 
adhesion to fibrin fibers formed on immobilized tissue factor, and, 
accepting the latter result over the former, they concluded that GPVI 
was not a functional platelet receptor for fibrin. The study by Zhang 
et al suggests that a different mechanism may be involved in platelet 
adhesion under flow.
Mammadova- Bach et al14 and Alshehri et al15 reported that fibrin 
enhances thrombin- induced platelet activation. Alshehri et al show 
that Syk and FcR- gamma phosphorylations were induced mainly 
through GPVI- dependent activation, but they were strongly en-
hanced in the presence of fibrin and thrombin. Onselaer et al16 later 
reported that the addition of fibrin induced weak platelet aggrega-
tion and platelet spreading on a fibrin surface, indicating that fibrin 
activated the platelets. Because the clot assay requires the addition 
of thrombin, it would be difficult to resolve activation by fibrin from 
thrombin- induced activation. Thus, it would be reasonable to admit 
that most of the platelets would be activated by thrombin. Only ac-
tivated platelets bind to fibrin,29 so they would bind to fibrin mainly 
through activated αIIbβ3. Our results thus suggest that GPVI may 
significantly contribute to the binding of resting platelets to fibrin.
To analyze the interaction of resting platelets with fibrin clots, 
we allowed resting platelets to adhere to the fibrin clot and ob-
served the morphology of the adhered platelets and fibrin (Figure 8). 
Control platelets bound to noncrosslinked fibrin showed that some 
platelets are spread, whereas spreading is slightly decreased by 
F I G U R E  8  Confocal images comparing platelets bound to noncrosslinked and crosslinked clots. Clots were formed with a mixture of 
unlabeled and Alexa Fluor 555- labeled fibrinogen (1 mg/ml final concentration) without (noncrosslinked clots) and with Ca2+ and factor XIII 
(crosslinked clots) by adding thrombin; details are described in the Methods. Platelets (control: no inhibitor, m- Fab- F: 100 μg/ml, Dasatinib: 
50 nM) were allowed to bind to the clots for 30 min, unadhered platelets removed from the clots and then the clots were fixed for each 
condition. Noncrosslinked clots: only a few platelets were spread on the noncrosslinked clots, the rest were round in shape, with evident 
fibrin colocalizing with integrin αIIbβ3 on the periphery of the platelets in the control. Dasatinib- treated prevented all spreading and 
decreased association with fibrin, compared with the controls, but the platelets still adhered. mFab- F did not affect the platelet binding, but 
in four of six preparations, there is apparently less fibrin bound around the platelet perimeter. Crosslinked clots: Control platelets were well 
spread on the crosslinked fibrin, and mFab- F did not affect this. Dasatinib appeared to decrease the number of well- spread platelets. None 
of the samples had evident fibrin colocalized on the platelet periphery, compared with those in the noncrosslinked clot
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mFab- F and strongly decreased by dasatinib, a tyrosine kinase in-
hibitor that strongly inhibits GPVI- induced platelet activation but 
only weakly inhibits thrombin and ADP- induced platelet activation 
through the inhibition of outside- in activation by integrin αIIbβ3.30,31 
Furthermore, control platelets show strong colocalization with fi-
brin(ogen) and integrin αIIbβ3 and the colocalization is decreased 
by mFab- F and dasatinib. These results suggest that platelets are 
weakly activated on fibrin and the activation is decreased by inhi-
bition of GPVI binding to fibrin and its activation pathway. Platelet 
activation by fibrin via the GPVI pathway has been reported in pre-
vious studies.14- 16 In contrast, platelet binding to crosslinked fibrin is 
very different. Most of the control platelets are spread on the fibrin, 
and mFab- F and dasatinib had little or no apparent effect, although 
dasatinib- treated platelets show filopodia and less spreading. In 
these crosslinked clots, we could not detect colocalization of inte-
grin αIIbβ3 and fibrin (ogen), which might be because crosslinked 
fibrin forms tightly packed fibrin fibers and fibrin is unable to move 
to the platelet surface. These results suggest stronger activation on 
crosslinked fibrin than on noncrosslinked fibrin, a phenomenon that 
should be explored in future studies.
This study resolves the question of which form of GPVI acts as 
the fibrin receptor. The dimer is the form of GPVI specifically in-
teracting with fibrin as a receptor and this is consistent with the 
expected higher avidity of dimeric receptors. From the analogy be-
tween collagen binding and fibrin binding by GPVI, we can make the 
following hypothesis: GPVI dimers bind to both collagen and fibrin 
fibers, but not to their monomeric forms (soluble collagen and fi-
brinogen, respectively). This means that a binding site specifically 
formed in the dimer comprising two GPVI monomers recognizes a 
complementary binding site in the tertiary structure of either type 
of fiber. It follows that GPVI monomers, which cannot form such a 
binding site, is unable to bind to either collagen or fibrin fibers.
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